| Risk | High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 1.29% |
| NAV | ₹202.34 (09 Jul 2020) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹2,992 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Aurobindo Pharma Ltd. | Healthcare | Equity | 12.0% |
| Cipla Ltd. | Healthcare | Equity | 10.4% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 10.1% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 10.0% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 8.8% |
| Lupin Ltd. | Healthcare | Equity | 8.1% |
| Syngene International Ltd. | Healthcare | Equity | 5.7% |
| Biocon Ltd. | Healthcare | Equity | 4.8% |
| Sanofi India Ltd. | Healthcare | Equity | 4.5% |
| Thyrocare Technologies Ltd. | Healthcare | Equity | 4.4% |
Nippon India Pharma Fund Direct Bonus is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Direct Bonus fund.The fund currently has an Asset Under Management(AUM) of ₹2,992 Cr and the Latest NAV as of 09 Jul 2020 is ₹202.34.
The Nippon India Pharma Fund Direct Bonus is rated High risk. Minimum SIP Investment is set to 100. Exit load of 1% if redeemed within 1 month.
To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.